Described is a case of acute chest syndrome in a sicklecell patient (hemoglobin SS) who also developed signs and symptoms of thrombotic thrombocytopenic purpura, including thrombocytopenia and hemolysis (anemia, elevated lactate dehydrogenase, presence of schistocytes, dark-colored plasma, and elevations in nucleated red blood cells). The ADAMTS13 activity level was normal. Discussed are the diagnosis and therapeutic management issues and the challenges of differentiating the vasoocclusive and hemolytic complications of sickling red blood cells from the thrombotic microangiopathy of thrombotic thrombocytopenic purpura.
Introduction
Vasoocclusive events (VOEs) in sickle-cell patients can cause tissue ischemia and infarction, which can manifest as pain, dactylitis, acute chest syndrome, splenic sequestration and autoinfarction, renal papillary necrosis, abdominal crisis, avascular necrosis of bones, priapism, and others. 1 The VOEs affecting the brain can cause transient ischemic attacks, thrombotic or hemorrhagic strokes, seizures, and other focal defects. 2 Some of the tissues affected in sickle cell crisis can also be affected in thrombotic thrombocytopenic purpura (TTP), and therefore have similar clinical presentations. The thrombotic microangiopathy of TTP can occur in an idiopathic manner or in conjunction with other clinical conditions, some of which demonstrate a deficiency in the ADAMTS13 metalloprotease that cleaves unusually large von Willebrand factor multimers. 3 The management of sickle cell crisis depends on the clinicopathologic condition and may include analgesics, adequate hydration, rest, incentive spirometry, and oxygenation. 1 To supplement oxygen delivery to affected tissues and to improve blood rheology, patients can receive red cell transfusions (straight or exchange transfusion). The first-line treatment for TTP is plasmapheresis with fresh frozen plasma, 4 with adjunctive immunosuppression in cases of acquired inhibitors to ADAMTS13. 5 We describe a patient with sickle-cell disease (hemoglobin SS) who presented with pain crisis and acute chest syndrome, but also exhibited clinicopathologic features of TTP, including thrombocytopenia, microangiopathic hemolytic anemia, and fever.
Case Report and Results
A 16-year-old African American female who presented with sickle-cell (hemoglobin SS) disease had developed headache and pain in her extremities, which progressed to respiratory distress, hypoxia, headache, and chest pain. A chest X ray showed left lung lingular infiltrate. She was febrile (T 38.3 C) and tachypneic (respiratory rate 22/min), with normal blood pressure. She had a nonfocal neurological exam, with a normal head computed tomography (CT) and head magnetic resonance imaging (MRI). Acute chest syndrome was diagnosed and erythrocytapheresis was performed, which reduced the hemoglobin S level to 4.8%. Purpuric lesions were noted over right biceps and palpable ecchymotic area on right lateral thigh. Lactate dehydrogenase (LDH) was elevated ( Figure 1 ) and a peripheral blood smear showed 1þ schistocytes. Given her sickle-cell disease and the unclear etiology of fevers, blood cultures were drawn and antibiotics were administered. The patient became afebrile during the hospital course and the blood cultures were negative at the time of discharge (day 17, Figure 1 ).
Other conditions such as disseminated intravascular coagulation were considered less likely, given the normal prothrombin time of 13.2 seconds (reference 11.7-13.5 seconds), normal activated partial thromboplastin time of 34.1 seconds (reference 24-37.5 seconds), 6 and negative direct antiglobulin testing, respectively.
Because of hemolytic anemia (elevated LDH, nucleated red blood cells), schistocytes, thrombocytopenia ( Figure 1 ), and headache, TTP was also considered. Therefore, daily plasmapheresis treatments were performed with fresh frozen plasma as the replacement fluid (hospital days 1-12). Prior to apheresis procedures, patient plasma was collected for ADAMTS13 protease activity, and was normal (complete absence of high-molecular-weight multimers) by immunoblot. 7, 8 Therefore, testing for an inhibitor to the ADAMTS13 protease was not required. (The ADAMTS13 results were not available until after initiation of plasmapheresis treatments). The plasmapheresis product collected in the initial plasmapheresis procedures was dark, consistent with intravascular hemolysis, but lightened with the subsequent procedures. The LDH was markedly elevated, but declined during the hospital stay ( Figure 1 ). However, the LDH level remained above the normal range, as can occur in sickle-cell patients. 9 The number of schistocytes declined from ''1þ'' to ''occasional'' (day 5-6) and then cleared by day 16. The nucleated red blood cell count was markedly elevated initially, but decreased over time. The hemoglobin levels were relatively stable, though this may have reflected red cell priming of certain plasmapheresis procedures (days 2, 8, and 11). After the platelet count exceeded 150 000/mL for 5 days (day 12), plasmapheresis was discontinued. The platelet count continued to steadily rise until discharge (day 17). As the platelet count recovered, the mean platelet volume declined (n ¼ 17, Pearson r ¼ À0.782, P ¼ .0002), suggesting a compensatory megakaryopoietic response to the initial thrombocytopenia. 10, 11 Similarly, the LDH declined as the hemoglobin recovered (n ¼ 17, Pearson r ¼ À0.63, P ¼ .007). 
Discussion
When 2 conditions can present in a similar way, a definitive diagnosis is challenging, especially if they require different treatments. On one hand, one can conclude that this patient did not have TTP, because most of the clinicopathologic features exhibited can be attributed to sickle crises, such as fever, anemia, 12 and nonfocal neurological symptoms, 12 like those of TTP. [12] [13] [14] Anemia can result from splenic sequestration, aplasia, or hyperhemolysis (sickle crisis) versus microangiopathic hemolysis (TTP). Thrombocytopenia can occur during pain crises, early in the onset of acute chest syndrome and multiorgan failure, 15 with a rebound thrombocytosis during recovery. 16, 17 However, due to functional hypospenism, sicklecell patients may not demonstrate as profound a thrombocytopenia as other TTP patients. 18 However, a question often arises: How to know if a patient in sickle crisis (primary condition) with complications that mimic TTP (second condition) does not also have TTP, especially given its morbidity and the benefit of plasmapheresis? 4 For example, the patient was an African American female, a demographic group more likely to develop TTP 3 (also more likely to have sickle-cell disease). Patients with sickle crisis or TTP could benefit from plasmapheresis, which reduces plasma cytokines and inflammatory mediators that adversely affect red cell rheology, and promote organ damage. 19, 20 In addition, plasmapheresis has effectively treated vasoocclusion in sickle-cell disease, when erythrocytapheresis alone was not effective. 21 On the other hand, if the underlying pathophysiology involved was that of TTP, the first-line treatment is plamapheresis, regardless of the ADAMTS13 status. 4, 22 The ADAMTS13 activity was normal in this patient, as in other sickle-cell patients during pain crises or in the asymptomatic intervals between crises. 23 This is not uncommon, as patients diagnosed with TTP often do not have reduced ADAMTS13 activity. 3 It is possible that other pathophysiological mechanisms may contribute to thrombotic microangiopathies, such as coagulation factor variants (eg, FactorXIII Val34Leu) that modulate fibrinolysis and increase the risk of thrombosis in TTP patients. 24 This patient had a markedly elevated LDH, suggestive of injury to tissue or red cells, both of which could result from the thrombotic microangiopathic effects of TTP or the vaso-occulsive complications of sickle-cell disease. This patient's LDH decreased, but did not return to normal levels, which is not unexpected, because sickle-cell disease patients can have twice the normal LDH level at baseline. 9 Of note, the LDH blood samples were drawn prior to each day's plasmapheresis (*20 hours following the previous procedure). Thus reductions in LDH levels are likely due to reductions in tissue damage or hemolysis and not an artifact of the analyte merely being removed in the plasmapheresis procedure.
The diagnosis of TTP and sickle-cell disease includes history and physical examination, complete blood count, and examination of peripheral blood smear. Thrombotic thrombocytopenic purpura can be diagnosed in cases of thrombocytopenia and microangiopathic hemolytic anemia (schistocytes) without another apparent cause. The more stringent classical pentad, which also includes neurological and renal involvement and fever, is uncommonly used, given the efficacy of therapeutic plasmapheresis and the need to initiate therapy promptly. 5 Sickle-cell disease is diagnosed by peripheral smear (sickled red blood cells and Howell-Jolly bodies [hyposplenia in sickle-cell disease]), sickling tests using reducing agents, and hemoglobin electrophoresis. 25 Depending on the organs involved, sickle-cell crisis can cause abnormalities on radiographic imaging (eg, infiltrates on chest X rays in acute chest syndrome; osteomyelitis or bone infarction on bone imaging; ischemia or hemorrhage on brain MRI/CT after stroke) and laboratory evidence of tissue damage (eg, isosthenuria due to renal papillary necrosis; unconjugated hyperbilirubinemia due to hemolysis). Likewise, in TTP, small-vessel microthrombi can lead to neurological changes (altered mental status, seizure, and stroke), renal dysfunction, and hemolysis.
